Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches

  title={Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches},
  author={Hans Thoenen and Michael Sendtner},
  journal={Nature Neuroscience},
  volume={5 Suppl 1},
Despite high enthusiasm, early attempts to develop clinical treatments based on animal research with neurotrophins were not successful. Here we survey clinical trials with neurotrophins, compared with neurotrophic factors of other gene families, and delineate the most likely reasons for their failure. We then suggest improved methods for regulated local supply of NTs to specific populations of neurons and discuss future therapeutic procedures evolving from the more detailed knowledge of the… 
Angels and demons: neurotrophic factors and epilepsy.
Modulation of neurotrophic growth factors as a therapeutic strategy for neuropathic pain
The apparent lack of translation from the bench to the clinic may be considered in the context of current understanding of the neurotrophic growth factors, especially mechanism of action, efficacy in animal models of disease, and safety and tolerability, and how these factors relate to clinical trial design.
Small-molecule modulation of neurotrophin receptors: a strategy for the treatment of neurological disease
By departing from conventional neurotrophin signalling, these ligands might provide novel therapeutic options for a broad range of neurological indications.
Neurotrophic Factors in Neurodegenerative Disorders
This review summarizes the current status and the efforts to treat neurodegenerative disorders by the exogenous administration of neurotrophic factors in an attempt to replenish trophic supply, the paucity of which may contribute to the development of the illness.
Gene therapy for the treatment of sensory neuropathy
The first human trial, using a plasmid to transfer the gene coding for vascular endothelial growth factor into muscle for the treatment of diabetic neuropathy, is now underway.
Neuroprotection and repair by neurotrophic and gliotrophic factors in multiple sclerosis
  • J. Loeb
  • Biology, Medicine
  • 2007
A greater understanding of axoglial biology is needed to understand the pathogenesis of MS and to develop biologically targeted new therapeutics, and how protein regulatory factors signal and how they are naturally targeted to axons and glia in both health and disease.
Trk Receptors and Neurotrophin Cross-Interactions: New Perspectives Toward Manipulating Therapeutic Side-Effects
New perspectives to the manipulation of side-effects via a better understanding of the cross-interactions at the molecular level are discussed, derived by computational methods.
Neurotrophin signalling: novel insights into mechanisms and pathophysiology.
The mechanism of action of neurotrophins and how BDNF/tropomyosin receptor kinase B (TrkB) receptor signaling can dictate trophic responses and change brain plasticity through activity-dependent stimulation are reviewed.
Integral Characterization of Defective BDNF/TrkB Signalling in Neurological and Psychiatric Disorders Leads the Way to New Therapies
This review highlights the relevance of an integrative characterization of aberrant BDNF/TrkB pathways for the rational design of therapies that by combining BDNF and TrkB targets could efficiently promote neurotrophic signalling.


Pharmacology of neurotrophic factors.
  • F. Hefti
  • Biology, Medicine
    Annual review of pharmacology and toxicology
  • 1997
The development of small molecule mimetics represents an alternative approach that is actively pursued to provide brain-penetrant neurotrophics in order to deliver neurotrophic factors into the brain.
Neurotrophic factors: from molecule to man
Nerve growth factor signaling, neuroprotection, and neural repair.
Expanded roles for NGF that are associated with the dynamically regulated production of NGF and its receptors that begins in development, extends throughout adult life and aging, and involves a surprising variety of neurons, glia, and nonneural cells are considered.
A controlled trial of recombinant methionyl human BDNF in ALS
Although the primary end point analysis failed to demonstrate a statistically significant survival effect of BDNF in ALS, post hoc analyses showed that those ALS patients with early respiratory impairment and those developing altered bowel function showed statistically significant benefit.
BDNF and epilepsy: too much of a good thing?
The many faces of p75NTR
Neuroprotective gene therapy for Huntington's disease using a polymer encapsulated BHK cell line engineered to secrete human CNTF.
It is expected that the gene therapy approach described in this protocol will mitigate the side effects associated with the peripheral administration of recombinant hCNTF and allow a well-tolerated, continuous intracerebroventricular delivery of the neuroprotective factor.
A new concept in neurodegeneration: TNFalpha is a silencer of survival signals.
Treatment of the more-devastating and costly neurodegenerative diseases of the authors' time might be best promoted by increasing the efficacy of neuronal survival factors using new approaches aimed at inhibiting the SOSS.
Neurotrophic cross‐talk between the nervous and immune systems: Implications for neurological diseases
Inflammatory reactions in the central nervous system usually are considered detrimental, but recent evidence suggests that they also can be beneficial and even have neuroprotective effects.